Aligos Therapeutics Partners with Xiamen Amoytop Biotech for the Development of ALG-000184
Shots:
- Aligos Therapeutics has signed a clinical trial collaboration agreement with Xiamen Amoytop Biotech per which Amoytop will fund and conduct P-Ib study of ALG-000184 for treating chronic hepatitis B (CHB) in Chinese patients post NMPA’s approval
- The P-Ib trial will assess the safety, PK & antiviral activity of ALG-000184 (300mg, QD, oral) + Pegbing + entecavir (ETV) vs ALG-000184/Pegbing + ETV in treatment naïve HBeAg-ve & nucleos(t)ide analog (NA) suppressed HBeAg-ve CHB patients for 48wks.
- The P-Ia studies of ALG-000184 showed linear PK, strong antiviral activity & its tolerability without any safety concerns while its long-term P-Ib monotx. studies achieved HBV markers reductions (DNA, RNA, HBsAg, HBeAg, HBeAg, HBcrAg)
Ref: Aligos Therapeutics | Image: Aligos Therapeutics & Xiamen Amoytop Biotech
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
